SAN ANTONIO (EGMN) - Granulocyte colony-stimulating factor-supported chemotherapy for breast cancer patients reduces overall mortality by about 2 per 100 treated patients but increases estimated absolute risk of acute myeloid leukemia or myelodysplastic syndrome by 3 per 1,000 compared with similar regimens without G-CSF support, according to a meta-analysis. "I call it a good news/bad news situation, but really I think the good news probably trumps the bad news," Dr. Gary H. Lyman observed at the...